<DOC>
	<DOC>NCT02044094</DOC>
	<brief_summary>This is a multiple-dose study in non-treatment seeking male and female subjects with moderate to severe opioid use disorder who meet criteria from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) to evaluate the effectiveness of RBP-6000 to block exogenous opioids.</brief_summary>
	<brief_title>Multiple Dose Study of Blockade of Opioid Effects of Injections of Buprenorphine in Participants With Opioid Disorder</brief_title>
	<detailed_description>A study of RBP-6000 300 mg administered via subcutaneous depot injections using the ATRIGEL Delivery System to determine whether there is a difference in the average score of subjective-effects questionnaires completed by study participants (using a visual analog scale (VAS)) after administering 6 mg or 18 mg hydromorphone compared to 0 mg hydromorphone (placebo) as an opioid blockade test (challenge).</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Analgesics, Opioid</mesh_term>
	<mesh_term>Hydromorphone</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<criteria>Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM5) criteria for moderate or severe opioid use disorder at screening and are not seeking opioid use disorder treatment Body mass index of &gt;= 18.0 to &lt;= 33.0 kg/m^2 Females women of childbearing potential (defined as all women who are not surgically sterile or postmenopausal for at least 1 year prior to informed consent) must have negative pregnancy test prior to enrollment and must agree to use a medically acceptable means of contraception from screening through at least 3 months after the last dose of study drug Male subjects with female partners of childbearing potential must agree to use medically acceptable contraception from screening through at least 3 months after the last dose of study drug Subjects with any current diagnosis requiring chronic opioid treatment Subjects who currently meet the criteria for diagnosis of moderate or severe substance use disorder by DSM5 criteria for any substances other than opioids, caffeine, or nicotine. Subjects who have abused or used buprenorphine within 14 days prior to informed consent. Other protocoldefined criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Opioid dependent</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Suboxone Film</keyword>
	<keyword>Opioid blockade</keyword>
	<keyword>Hydromorphone challenge</keyword>
</DOC>